This conference call took place on May 6, 2014. Let's call it a 16 month forecast. Shall we check the results? How about 0% of the projections came true. in 2013, the CEO said the SEC Investigation would be closed by Q1 2014. This is the follow up. Management claims MSLP will be .41-.51 EPS positive for 2014. Look at the new product forecasts. None were launched to my knowledge. Yet some here pretend when MSLP issues press releases they are meaningful in some respect. Read this and you realize it is all about penny stock promotion tactics.
Jack Wallace - Sidoti & Company This large major competitor, they wouldn’t happen to be a major sponsor of the NFL, would they? You’ll have to answer that question. And then lastly, any status on the SEC investigation; is the timeline still hopefully soon and then after the SEC investigation is completed, assuming nothing surprises there, what would be the timeline to go ahead uplift to the NASDAQ?
Brad Pyatt - Chief Executive Officer We're continuing to work with the SEC; it’s taken longer, like I said in our call in March, longer than we anticipated. However, we're not finding anything that is alarming to us that is going to hurt our company long-term. We knew like I said as a young CEO, I could have probably done it better but again, which you don’t know, you don’t know until you know it. And I know a lot more now and that’s why I have the team around me that I have that’s helping me in protecting us, so we don’t go through this again. But the timing on the -- we're hoping this is done sometimes this quarter. However, I can’t control them. I am hoping Q2, Q3, realistically is done. We're pushing for Q2 but again the SEC is -- we don’t want to force them to do something until they are done with their full process. And again we think as soon as that happens, the NASDAQ is -- realistically going to happen and as soon as possible after that. We're timing the NASDAQ before the year-end. That’s what we're really hoping for. It could be sooner, if the SEC comes back with their investigation being concluded before them but that's -- we're kind of just waiting on that.
Jack Wallace - Sidoti & Company Okay. Thank you. That will be all for me for now.
Operator
Our next question is coming from Peter Black of Wynnefield Capital. Please proceed with your question.
Peter Black - Wynnefield Capital Good morning, guys. Great results. I just had one question and in terms of the BioZone acquisition, you mentioned that there might be some new products, new products coming from that. What types of new products could we expect? And then, the second question around BioZone is should BioZone eventually be accretive to your margins?
Brad Pyatt - Chief Executive Officer Yes. So I'll handle the first question and let Richard handle the second one. As far as new products, the first one we're launching which will probably be Q4, late Q3 to early Q4 is our DROPZ energy product. We've teamed with ChromaDex to utilize their technology on their pure energy which is pterostilbene and caffeine, which is crystallized caffeine that allows you to get a safer way of getting the energy.
So that's one of the first products that we have used our innovative Qzone technology to make. It allows us to get into a new market, which is the energy market which is huge. And then in addition, we are also leveraging this with our Musclegel product, which we had a lot of issues of Musclegel from manufacturer being able to get it right. And we really have -- it's done well for us but it has done as we well as we wanted to do, because we haven't really promoted it due to the manufacturers not been able to get the manufacture process right. With BioZone and controlling that we’re very confident on the Musclegel product that we can give -- deliver the same taste, same experience from the way -- the texture of it where other manufacturers was inconsistent that. Now with Musclegel, we can really start ramping that product up and that one is very exciting to us because we think that product is -- it’s always been a favorite, everyone tries it, it’s just never really been marketed right because we weren’t confident that the manufacturer would have the ability to scale with as BioZone that allows us to scale now with that product.
Richard Estalella - President and COO Yes. And again anything in the liquids; creams and gels category, that’s why this was such a strategic acquisition and that our existing strategic partners from a contract manufacturing standpoint did point posses that expertise. So now, we bring that in house and we can continue to expand not only within the sports nutrition category but in contract manufacturing in general. So, we are very proud of our accomplishments in Q1, our first quarter with BioZone under our belt. In the acquisition quarter, we took an entity that had previously quarter-over-quarter lost a significant amount of money and we are slightly above breakeven in Q1. So, I think it speaks to our ability to integrate, acquire and expand quickly and kind of again optimize when we do transactions like this. And hopefully it’s a first of many to come. So it was very, very successful and we see a lot of upside in the remainder of the year. We should see some of these new products that we are talking about launching in Q4, but primarily most of these will be tuned up for 2015. But again, we should start seeing some of in Q4.
Peter Black - Wynnefield Capital Great, thanks a lot, I appreciate it.
Thank you. Our next question is coming from Jay Burnham of Armory Advisors. Please proceed with your question.
Jay Burnham - Armory Advisors Hi, thanks. My first question is back on the guidance. Can you give me a little more color on the earnings guidance? You’re only looking for $0.18 to $0.28 for the rest of the year. Just wondering, is that a function of a low tax rate in the first quarter and will you be a tax payer the rest of the year and also are there anymore I don’t know, additional expenses in the rest of the year that resulted in the earnings?
Don Prosser - Chief Financial Officer I’ll talk about the tax rate. From a tax situation, we had some Canada tax and that was in the first quarter which we’re dealing with exploring how that’s going to work out. As far as the federal income tax goes, we have the large NOL and don’t expect to have any tax in this year. So, none of that earnings per share has any tax in it. We’re expecting also that as we’re building our team and doing all this out, our overhead is just going to stay like Richard talked about with the additional headcount. So, we believe that we’re comfortable that $0.41 to $0.51 per share and there is no tax.
